Pralatrexate is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death.
Related Prodcuts:
Fidaxomicin; Marbofloxacin; CP-466722; TTP 22; D-64131; M344; CHIR-124; Reversine; XL228; VE-822; RI-1; SRPIN340; XL888; Rigosertib; APY29; NMS-873; PF-03758309; Telatinib